PPLUIS ECHEGARAY, M.D.
Pulmonary Function Technologist in GUAYNABO, Puerto Rico. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PPLUIS ECHEGARAY, M.D. reported a CMS MIPS final score of 28.2742/100 — below the 83.1 national average — and filed 13,896 Medicare Part D claims in 2023.
- 28.2742/100
- MIPS score · -55 vs avg
- 14K
- Part D claims, 2023
- 63%
- generic prescribing
- $124.16
- industry payments (Sunshine Act)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PPLUIS ECHEGARAY, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
28 3rd percentile higher than 3% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
What does the federal data show about PPLUIS ECHEGARAY, M.D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Puerto Rico
How Pulmonary Function Technologist compares to other specialties among Puerto Rico providers
Pulmonary Function Technologist share within Puerto Rico
Pulmonary Function Technologist is one of the more visible NUCC categories in Puerto Rico
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
PPLUIS ECHEGARAY, M.D.'s 2023 MIPS final score plotted against the Pulmonary Function Technologist national average
- MIPS Final Score
- 28.2742/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Pulmonary Function Technologist) — 28.2742/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Cost dim CMS Cost category
- Specialty volume Pulmonary Function Technologist US NPIs
28.2742/100 MIPS final score — 54.8 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Pulmonary Function Technologist. Quality dim: 0. Cost dim: 94.2473.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PPLUIS ECHEGARAY, M.D. appears in the CMS NPPES registry as a Pulmonary Function Technologist provider holding M.D. credentials at MARAMAR PLAZA 1250, GUAYNABO, PR, 00968, with a listed phone of (787) 200-4545. NPI 1639124977 was issued on 05/24/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ECHEGARAY most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 13,896 prescription claims written by this provider, covering 1,519 Medicare beneficiaries and totaling roughly $3.2 million in drug spend, split 37% brand-name and 63% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 28.2742/100 for the 2023 performance year (Quality 0, Cost 94.2473), compared with the national average of 83.1.
Pulmonary Function Technologist is a narrow specialty nationwide, with 72 enrolled providers across 26 states and an average of 8,989 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1639124977 |
|---|---|
| Specialty | Pulmonary Function Technologist |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 05/24/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PPLUIS ECHEGARAY, M.D.'s current license status, disciplinary history, and board certifications directly with the licensing state's medical board before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PPLUIS ECHEGARAY, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$124
Largest payer
AstraZeneca Pharmaceuticals LP
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Above average
37% brand-name claims vs 63% generic, on 13,896 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 16,218
- Total Day Supply
- 452,033
- Brand vs Generic
- 37% brand / 63% generic
- Brand Drug Cost
- $3.0M
- Generic Drug Cost
- $206K
- Antibiotic Claims
- 396
Patient Demographics
- Average Patient Age
- 72.9 years
- Avg HCC Risk Score
- 1.61
- Gender Split
- 66% female / 34% male
- Age Distribution
- <65: 168, 65-74: 746, 75-84: 460, 85+: 145
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PPLUIS ECHEGARAY, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Montelukast Sodium
Montelukast Sodium
4,382 claims
- Symbicort 1,664
Symbicort
1,664 claims
- Prednisone 1,605
Prednisone
1,605 claims
- Fluticasone Propio… 939
Fluticasone Propionate
939 claims
- Albuterol Sulfate … 925
Albuterol Sulfate Hfa
925 claims
- Spiriva Respimat 741
Spiriva Respimat
741 claims
- Breo Ellipta 681
Breo Ellipta
681 claims
- Budesonide-Formote… 566
Budesonide-Formoterol Fumarate
566 claims
| Drug | Claims |
|---|---|
| Montelukast Sodium | 4,382 |
| Symbicort Budesonide/Formoterol Fumarate | 1,664 |
| Prednisone | 1,605 |
| Fluticasone Propionate | 939 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 925 |
| Spiriva Respimat Tiotropium Bromide | 741 |
| Breo Ellipta Fluticasone/Vilanterol | 681 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 566 |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 284 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 187 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pulmonary Function Technologist Overview
How PPLUIS ECHEGARAY, M.D. fits within the Pulmonary Function Technologist landscape nationally.
PPLUIS ECHEGARAY, M.D.'s 13,896 claims are above the specialty average of 8,989.
Nearby Pulmonary Function Technologist Providers in Puerto Rico
Other clinicians with the same primary specialty enrolled in Puerto Rico, drawn from the same CMS NPPES roster as ECHEGARAY.
Compare Pulmonary Function Technologist nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Puerto Rico
Frequently Asked Questions
What is PPLUIS ECHEGARAY, M.D.'s specialty? ▼
How much does PPLUIS ECHEGARAY, M.D. prescribe under Medicare Part D? ▼
What is PPLUIS ECHEGARAY, M.D.'s Medicare quality score? ▼
Where is PPLUIS ECHEGARAY, M.D. located? ▼
What is PPLUIS ECHEGARAY, M.D.'s NPI number? ▼
Does PPLUIS ECHEGARAY, M.D. prescribe more brand-name or generic drugs? ▼
How many Pulmonary Function Technologist providers are there in the US? ▼
What drugs does PPLUIS ECHEGARAY, M.D. prescribe most often? ▼
Does PPLUIS ECHEGARAY, M.D. accept Medicare? ▼
How can I verify PPLUIS ECHEGARAY, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology